<DOC>
	<DOC>NCT01012388</DOC>
	<brief_summary>Post marketing study to assess the likelihood of hypertropic scarring, keloid formation and hyper- or hypopigmentation in patients with Fitzpatrick Skin Types IV, V, and VI receiving nasolabial fold treatment with Radiesse® Injectable Dermal Filler</brief_summary>
	<brief_title>Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color</brief_title>
	<detailed_description />
	<criteria>Is at least 18 years of age. Has Fitzpatrick Skin Type IV, V, or VI. Understands and accepts the obligation not to receive any other procedures or treatments in the nasolabial fold for 6 months. Has history of hyper or hypopigmentation in the nasolabial folds, keloid formation, or hypertrophic scarring. Has a known bleeding disorder or is receiving drug therapy that could increase the risk of bleeding. Has nasolabial folds that are too severe to be corrected in one treatment session. Has received any dermal filler or other injections, grafting or surgery in either nasolabial fold. Is pregnant, lactating, or not using acceptable contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Moderate to severe wrinkles and folds such as nasolabial folds</keyword>
</DOC>